story of the week
Survival Outcomes With De-Escalated Neoadjuvant Pertuzumab Plus Trastuzumab With or Without Weekly Paclitaxel in HER2+/HR− Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Lancet Oncol 2022 Apr 08;[EPub Ahead of Print], U Nitz, O Gluz, M Graeser, M Christgen, S Kuemmel, EM Grischke, M Braun, D Augustin, J Potenberg, K Krauss, C Schumacher, H Forstbauer, T Reimer, A Stefek, HH Fischer, E Pelz, C Zu Eulenburg, R Kates, R Wuerstlein, HH Kreipe, N HarbeckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.